Secukinumab treatment in psoriasis patients with liver condition
Part of Digestive system, Hormones & metabolism, Skin clinical trials.
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriasis (with or without psoriatic arthritis) and a liver condition called MASLD.
- You started taking secukinumab between January 2021 and December 2023.
- You are 18 years or older at the time you started the drug.
- Secukinumab is your first, second, or third biologic treatment for psoriasis.
- You have at least one risk factor for heart or metabolic problems, like high blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study looks at how well a psoriasis medicine called secukinumab works, and what happens when treatment is stopped in people with moderate-to-severe plaque psoriasis. It may help show the best way to manage symptoms and prevent flare-ups.
This trial tests if adding metformin to secukinumab improves psoriasis in overweight or obese patients. If you have moderate-to-severe plaque psoriasis and a BMI of 25 or higher, this study may offer a new treatment option.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study looks at how well xeligekimab works for people with moderate to severe plaque psoriasis in everyday medical practice. It may help you if you are about to start this treatment for the first time.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.